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A pilot study demonstrating the 
altered gut microbiota functionality 
in stable adults with Cystic Fibrosis
F. Fouhy1, N. J. Ronan2,3, O. O’Sullivan  1,4, Y. McCarthy3, A. M. Walsh1,4, D. M. Murphy2,3, M. 
Daly3, E. T. Flanagan2,3, C. Fleming3, M. McCarthy3, C. Shortt3, J. A. Eustace2, F. Shanahan4,5, 
M. C. Rea1,4, R. P. Ross1,4,6, C. Stanton1,4 & B. J. Plant2,3,4,5
Cystic Fibrosis (CF) and its treatment result in an altered gut microbiota composition compared to 
non-CF controls. However, the impact of this on gut microbiota functionality has not been extensively 
characterised. Our aim was to conduct a proof-of-principle study to investigate if measurable changes 
in gut microbiota functionality occur in adult CF patients compared to controls. Metagenomic DNA was 
extracted from faecal samples from six CF patients and six non-CF controls and shotgun metagenomic 
sequencing was performed on the MiSeq platform. Metabolomic analysis using gas chromatography-
mass spectrometry was conducted on faecal water. The gut microbiota of the CF group was significantly 
different compared to the non-CF controls, with significantly increased Firmicutes and decreased 
Bacteroidetes. Functionality was altered, with higher pathway abundances and gene families involved 
in lipid (e.g. PWY 6284 unsaturated fatty acid biosynthesis (p = 0.016)) and xenobiotic metabolism 
(e.g. PWY-5430 meta-cleavage pathway of aromatic compounds (p = 0.004)) in CF patients compared 
to the controls. Significant differences in metabolites occurred between the two groups. This proof-
of-principle study demonstrates that measurable changes in gut microbiota functionality occur in CF 
patients compared to controls. Larger studies are thus needed to interrogate this further.
Cystic Fibrosis (CF) is an autosomal recessive disorder affecting over 70,000 individuals globally1, 2. Caused by a 
mutation to the cystic fibrosis transmembrane conductance regulator (CFTR) gene, it results in an altered flow 
of chloride and bicarbonate ions across epithelial cells, the most significant result of which is the dehydration of 
the airway surface liquid layer in the lungs, resulting in the accumulation of thick mucus. As a result, bacteria can 
colonize this mucus layer more efficiently and develop into CF pathogens3. While the lungs are the most seriously 
affected organ in CF and unsurprisingly have received the greatest research focus to date, the CFTR protein is 
located throughout the body on the apical layer of the epithelial cells, thus resulting in multiple morbidities, 
including altered gastrointestinal functioning.
Multiple factors contribute to the altered gut microbiota in patients with CF including, the CFTR mutation 
resulting in increased mucus secretions in the small intestine4, altered diet and the use of pancreatic enzymes. 
Undoubtedly one of the most influential factors that results in alterations to the CF gut microbiota is the lifelong 
exposure to oral, inhaled and intravenous antibiotics5. The impact of antibiotics on the gut microbiota has been 
extensively studied in a non-CF cohort and shown to have significant effects, with recovery of the microbiota 
to the pre-treatment state often being slow or incomplete6–9. Studies using DNA based approaches, including 
next-generation sequencing, have shown the CF gut microbiota to be significantly different to the gut microbiota 
of non-CF controls10, 11. One study used DGGE fingerprinting to investigate the predominant faecal microbiota of 
paediatric patients with CF compared to their healthy non-CF siblings12. The results demonstrated that clostridia, 
Bifidobacterium spp., Veillonella spp. and Bacteroides-Prevotella spp. were consistently higher in siblings com-
pared to those with CF. Additionally, a recent study identified the potential role of the CF mutation on the CF 
gut microbiota13. The study demonstrated that those who were homozygous-F508del had a more altered faecal 
microbiota compared to the other CF genotypes in the study cohort. Finally, the importance of understanding 
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changes in the CF gut microbiota was reinforced in light of a recent study that demonstrated that changes to the 
gut microbiota may presage changes in lung microbiota14.
The majority of next-generation sequencing studies to date have relied on sequencing of the 16S rRNA bac-
terial gene. While these approaches have provided important insights into the CF lung15, 16 and gut microbi-
ota10, the functionality of the altered CF microbiome has been poorly characterised. A recent study investigated 
the functionality of the CF lung microbiota using DNA and RNA sequencing17. However, there is a deficit of 
data regarding the CF gut microbiota, with no study examining functionality of the adult CF gut microbiota 
using shotgun metagenomic sequencing. A recent metagenomic study on the gut microbiota functionality of CF 
children (<3 years) demonstrated an altered functional capacity compared to non-CF children18. However, the 
authors suggested that this altered functionality was diminished with age. Thus, this pilot study wanted to take 
the first steps to investigate if in fact there would be measurable changes to the gut microbiota functionality in 
an adult CF population. Moreover, we wanted to investigate the metabolite profile of adult CF patients compared 
to controls. Our results showed significant changes in the functional diversity of the CF gut compared to the 
controls. Additionally, metabolites and gut microbiota were significantly altered in the CF group compared to the 
non-CF controls.
Results
Functional analysis. We studied the microbiota composition and functionality of the CF patients compared 
to the controls, using the HUMAnN2 analysis pipeline.
Of the 2066 pathways, 10.7% were found at significantly different abundances in the CF group compared to 
the controls. A PCA plot was also generated on the relative abundances of pathways in the CF and control patients 
(Fig. 1A). The plot showed clustering of the CF samples distinctly from the controls. A heat map demonstrated 
similar clustering of controls from CF patients based on pathway abundances (Fig. 1B), though in this instance, 
Figure 1. PCA plot (A) and a heat map (B) of pathway abundances based on pathways that were significantly 
altered between the two groups.
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CF2 was more similar to the controls than the CF patients. Two of the six CF patients (CF4 and CF5) were pancre-
atic sufficient. However, they did not cluster more closely together or appear more similar to each other compared 
to the four pancreatic insufficient patients. Diversity analysis on the pathway abundances was completed on both 
groups, with significantly lower pathway abundance diversity in the controls compared to the CF group (Shannon 
Index p = 0.01).
Lipid metabolism pathways. Pathways involved in unsaturated fatty acid biosynthesis (PWY 6284) 
(p = 0.016), fatty acid biosynthesis (PWY 6285) (p = 0.025) and palmitoleate biosynthesis (PWY 6282) (p = 0.025) 
were significantly increased in the CF patients. Furthermore fatty acid elongation FASYN-ELONG-PWY 
(p = 0.025), fatty acid oxidation (PWY 2501) (p = 0.01), super pathway of fatty acid biosynthesis PWYO-881 
(p = 0.025) and fatty acid and β-oxidation V PWY66–391 (p = 0.05) were all significantly increased in CF patients 
compared to controls. Using the pathway abundance data from HUMAnN2 we identified in which bacteria the 
pathways were found in and their relative abundance. From this information, we could ascertain pathways that 
were present in a higher abundance in CF patients compared to controls, due to the fact that a limited number 
of bacteria were increased in CF patients compared to controls. It was apparent that increased Ruminococcus, 
Clostridia, Enterococcus and Eggerthella resulted in the increased pathway abundances compared to the controls, 
thus signifying even small changes in microbiota can have a measurable impact on microbiota functionality.
Protein metabolism. The gut microbiota of the CF group exhibited several significant alterations to path-
ways involved in protein metabolism compared to the controls. The pathway abundances of arginine degradation 
ARGASEDEG-PWY (p = 0.01), homomethionine biosynthesis PWY 1186 (p = 0.025), tryptophan degrada-
tion pathway V PWY 3162 (p = 0.006) and L cysteine biosynthesis PWY 7289 (p = 0.05) were all significantly 
increased in those with CF compared to the controls.
Carbohydrate metabolism and pentose phosphate pathway. With respect to carbohydrate metab-
olism, the lactose utilization pathway (LACTOSEUTIL-PWY) was increased in the gut microbiota of those 
with CF compared to controls (p = 0.025). This could be seen with an increased abundance of this pathway in 
Ruminococcus gnavus (p = 0.014), R. torques (p = 0.007), C. clostridioform (p = 0.005) and E. faecalis (p = 0.007) 
in CF compared to controls. Additionally, starch degradation pathway (IV) PWY-6735 (p = 0.006) and pathway 
I PWY-842 (p = 0.010) abundances were significantly increased in the gut microbiota of the CF group compared 
to the controls. It was noted that the levels of these pathways in Bacteroides, Lachnospiracheae, Clostridium and 
Enterococcus were significantly increased in the CF patients compared to the controls, which could contribute to 
the altered starch catabolic pathways.
There were significant changes to the pentose phosphate pathways. Pentose phosphate pathway (oxida-
tive branch II) OXIDATIVEPENT-PWY-1 was significantly increased in abundance in the CF patients com-
pared to the controls (p = 0.016). Additionally, the non-oxidative branch of the pentose phosphate pathway 
NONOXIPENT-PWY was increased (p = 0.037) compared to the controls.
Xenobiotic degradation. Given the higher exposure of individuals with CF to antibiotics and therapeutic 
medicines compared to non-CF controls, we were interested in the impact this may have on the gut micro-
biota and the potential increases in bacteria capable of degrading xenobiotic compounds. The results showed 
that there were significantly increased abundances of pathways involved in xenobiotic metabolism in the CF gut 
microbiota compared to the controls, including PWY-5178 toluene degradation IV (p = 0.004), PWY-5430 meta 
cleavage pathway of aromatic compounds (p = 0.004), 4TOLCARBDEG-PWY 4 tolenecarboxylate degradation 
(p = 0.025) and PWY-5179 toluene degradation V (aerobic) (p = 0.028).
Folate metabolism and antibiotic biosynthesis. Some interesting non-significant increases in pathway 
abundances were also noted namely in folate metabolism and antibiotic biosynthesis. There was a non-significant 
trend of increase in folate transformations in the CF gut microbiota compared to the controls. We also noted 
there were higher abundances of antibiotic biosynthesis pathways in those with CF compared with controls. These 
included gentamicin biosynthesis PWY-7025 (5066 vs. 4594 in CF vs. control gut microbiota), neomycin PWY 
7016 (13.7 vs. 9.17 CF vs. control), paromycin biosynthesis PWY 7018 (1891 vs. 1575 CF vs. control), fosfomycin 
biosynthesis PWY 5757 (3.45 vs. 1.92 in CF vs. control gut), kanamycin biosynthesis PWY 7000 (3.34 vs. 2.75 CF 
vs. control) and streptomycin biosynthesis PWY 5940 (79.0 vs. 68.5 CF vs. control gut).
Gene abundance analysis based on gene ontology (GO). Metabolic functions. With respect to meta-
bolic functions, the relative abundance of 109 functions out of 654 (16.7%) were significantly altered between the 
groups. Interestingly, the relative abundance of only two metabolic functions were increased in the control group 
compared to the CF group - namely GO: 0004717 transmembrane receptor protein tyrosine kinase and GO: 
00018024 histone-lysine N-methyltransferase activity. Some notable increased gene family abundances occurred 
in the gut microbiota of the CF group compared to controls, including genes involved in antibiotic resistance. 
These included O acetlytransferase activity (involved in acetylation of aminoglycosides conferring resistance to 
the bacterial host) (GO: 0016413; p = 0.006), drug transmembrane transporter activity (GO: 0015238; p = 0.01), 
porin activity (GO: 0015288; p = 0.025) and penicillin binding (GO: 0008658; p = 0.037). Using bacterial spe-
cies information, we examined the bacteria responsible for the significantly increased abundance of these gene 
families in the CF gut compared to the controls. It was found that significantly higher levels of these pathways 
occurred in Clostridium, Blautia, Lachnospiraceae, Bacteroides and Enterococcus, while extremely low levels 
or absence of these gene families in these bacteria occurred in the control group, owing to decreased levels or 
absence of these bacteria and their associated pathways in the control group (Fig. 2).
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Cellular components and biological processes. With respect to gene families involved in cellular com-
ponents, 13% were significantly increased in the CF group compared to the controls. These included significant 
increases in nucleosome (GO: 0000786; p = 0.037), plasma membrane (GO: 0005886; p = 0.016) and bacterial 
type flagellum (GO: 0009288; p = 0.037).
To investigate changes in biological processes, we looked at amino acid, lipid and carbohydrate metabolism, 
as well as xenobiotic degradation (which was of particular interest within a CF cohort due to their chronic expo-
sure to antibiotics and pharmaceuticals from an early age). With respect to protein metabolism, 278 processes 
were identified, of which 16 were significantly increased and just one was decreased in the gut microbiota of the 
CF group compared to the controls (significant results shown in Supplementary Table S3). The results confirm 
findings of the increased pathway abundances including increased tryptophan and arginine metabolism (GO: 
0000162; p = 0.037, GO: 0006568; p = 0.037, GO: 0010121; p = 0.037).
Of the 268 gene families involved in lipid metabolism, 22 were significantly different between the CF and 
control groups, five of which were increased in the controls compared to the CF group (Supplementary Table S3). 
The results indicated that the gut microbiota of individuals with CF has enhanced abundances of genes contrib-
uting to lipid metabolism including fatty acid biosynthesis (GO: 0006633; p = 0.016), fatty acid elongation (GO: 
0030497; p = 0.025) and methyl-branched fatty acid metabolic processes (GO: 0097089; p = 0.022).
Seventy-two of the 276 gene families involved in carbohydrate metabolism were significantly different between 
the two groups, the majority of which (75.4%) were significantly increased in the gut microbiota of the CF group 
Figure 2. Cladogram presenting the microorganisms detected in stool samples from CF patients and controls 
using MetaPhlAn2, and the relative contribution of each microbial species to unsaturated fatty acid biosynthesis 
and xenobiotic metabolic processes, as determined by HUMAnN2. Pink clades indicate that taxa were 
significantly higher in CF patients whereas cyan clades indicate that taxa were significantly higher in controls. 
Stars are used to highlight species that were significantly different between the two groups. The outer rings 
indicate the abundance of unsaturated fatty acid biosynthesis pathways (blue) and xenobiotic metabolic process 
pathways (red) that was assigned to each species by HUMAnN2.
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compared to the controls (Supplementary Table S3). These included polysaccharide biosynthetic processes (GO: 
0000271; p = 0.025), starch catabolic processes (GO: 0005983; p = 0.025) and pectin metabolic processes (GO: 
0045488; p = 0.037). Due to the higher exposure to and chronic use of antibiotics and other pharmaceutical ther-
apeutics in the treatment of CF, we were interested in investigating changes in the abundance of genes involved 
in xenobiotic degradation. We found four significant xenobiotic metabolic processes in the CF group compared 
to the controls (Supplementary Table S3) including enhanced xenobiotic metabolic (GO: 0006805; p = 0.01) and 
catabolic processes (GO: 0042178; p = 0.01).
To examine the combined effect of these changes to gene families, we used the GO terms to create a 3D scatter 
plot of our two groups. Initially (Fig. 3A) we used lipid (GO: 0006629), carbohydrate (GO: 0005975) and protein 
metabolism (GO: 0006250) as the three principle axes. The results show that the CF and control samples cluster 
separately, with only a slight overlap of the two clusters. The CF samples were higher in lipid and carbohydrate 
metabolism gene families, while the controls located closer to the protein metabolism axis. To investigate the 
effect of xenobiotic metabolic processes, we replaced the amino acid metabolism axis with xenobiotic metabolic 
processes (GO: 0006805) (Fig. 3B). Again, two clusters formed with the CF and the control samples clustering 
separately. The CF samples were higher in lipid and xenobiotic metabolism gene family abundances.
Phylogenetic investigations. To investigate the phylogenetic composition of our two groups, we extracted 
taxonomic data using MetaPhlan from the metagenomic data. Using the Graphlan package we analysed the phy-
logenetic composition of the two groups19, 20. Figure 4 shows the microbial populations present in the CF (A) and 
Figure 3. 3D Scatter plot of the CF and control samples using the gene abundance data and the GO terms 
lipid metabolism, carbohydrate metabolism and amino acid metabolism as the principle coordinates. 
x-axis = GO:0005975|BP|03| carbohydrate metabolic process, y-axis = GO:0006629|BP|03| lipid metabolic 
process, z-axis = GO:0006520|BP|03|cellular amino acid metabolic process (Panel A) or xenobiotic metabolism 
z-axis = GO:0006805|BP|03|xenobiotic metabolic process (Panel B).
Figure 4. Graphlan generated phylogenetic tree of 16S rRNA based phylogenetic composition of the CF (A) 
and control (B) groups. CF legend: A: Actinobacteria (red), B: Bacteroidetes (yellow), C: Firmicutes (green), 
D: Proteobacteria (purple), E: Verrucomicrobia (orange), F: Viruses (grey). Control legend: A: Archaea 
(blue), B: Actinobacteria (red), C: Bacteroidetes (yellow), D: Firmicutes (green), E: Proteobacteria (purple), F: 
Verrucomicrobia (orange), G: Viruses (grey).
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control (B) groups. The results indicate significant changes to the microbiota present in the CF group compared to 
the controls. The CF group had increased Firmicutes, decreased Actinobacteria, Bacteroidetes and Proteobacteria 
compared to the controls. Archaea were only detected in the control group. Levels of viruses and Verrucomicrobia 
were comparable between the two groups.
When statistical analysis was performed on the relative abundance of bacteria present, there were nota-
ble statistically significant differences between the gut microbiota in both groups (Table 1). At genus level, 
Bifidobacterium (3.21 (CF) vs. 6.81% (control) relative abundance; p = 0.05) and at species level, B. longum was 
significantly decreased in the CF group (2.12 vs. 4.32% relative abundance; p = 0.046) compared to the controls. 
With respect to the changes within the phyla Bacteroidetes, Barnsiella intestinihominis was absent in the CF group 
compared to the controls (p = 0.007). The greatest number of differences between the groups was seen within 
the Firmicutes phylum. Of particular note was the significantly higher levels of Enterococcus faecalis (8.83 vs. 0% 
relative abundance p = 0.007) compared to the controls (in whom this bacterium was not detected). Additionally, 
significant increases in Clostridium were seen in the CF group (p = 0.004) and C. hathewayi was only detected in 
the CF gut microbiota and not in the controls. There was a significant decrease in Faecalibacterium prausnitzii in 
the CF group compared to the controls (p = 0.003), while Ruminococcus gnavus and R. torques were significantly 
increased in the CF group (p = 0.022 and 0.013 respectively). Additionally, Blautia and Lachnospiracheae were 
only detected in the CF samples and not in the controls. Such changes in microbiota reflect the altered pathway 
abundances between the groups, as altering the microbiota prevalence results in altered abundance of their asso-
ciated pathways.
qPCR to investigate the microbial load in the CF and control gut microbiota. To verify that the 
phylogenetic changes are not indicative of alterations in the total microbial load in the CF gut compared to the 
controls, qPCR analysis was conducted on total bacterial DNA from all study participants. The qPCR analysis 
found no significant differences in 16S rRNA gene copy number/g faeces between the two groups (1.59 × 108 
(CF) vs. 3.07 × 108 (control); p = 0.150), thus alterations in the microbiota do not result from differences in total 
bacteria load between the two groups.
GC-MS results. To investigate the impact of an altered gut microbiota on metabolites, faecal water from the 
two groups was analysed using GC-MS. In the PCS model, the first three principle components all contribute to 
a partial separation of the groups, with the CF (red) and the control (green) samples forming distinct clusters 
(Fig. 5). Some overlap between the groups is seen, indicating some shared metabolites between CF patients and 
controls. Using the unsupervised PCA model, there was a clear tendency towards a grouping of two classes. The 
supervised method PLS-DA was used in an effort to find common characteristics for the two sample groups. The 
resulting predictions on the test are shown in Supplementary Fig. S1, where the lower plot shows the predictions 
of the sample. Samples with values higher than 0.5 are predicted to be from CF samples and those with values 
lower than 0.5 are predicted to be from the controls. As can be seen in Supplementary Fig. S1, all samples were 
correctly classified. This indicates that it is possible to find a set of common characteristics between the CF and 
control samples respectively. Variables with values above zero in the regression vector tend to be high in CF sam-
ples, while those lower than zero tend to be low compared to the control samples.
Statistical analysis was carried out on the non-parametric relative concentrations for each metabolite from 
the CF and control samples. Of the 99 metabolites, 16 were significantly different between the groups, with 15 of 
these being significantly higher in the CF samples compared to the controls. Significant increases were seen in 
hexadecanoic acid (p = 0.037), myristic acid (p = 0.037) and 9-octadecenoic acid (p = 0.025) in the CF samples 
compared to the controls (Supplementary Table 4). To elucidate similarities in clustering of metabolomic and 
metagenomic data, Procrustes and co-inertia analysis were performed (Supplementary Fig. S2). A strong positive 
correlation (r2 = 0.81) was observed using both co-inertia and Procrustes analysis between the metabolites and 
the pathway abundances, indicating similar clustering of both metagenomic and metabolomic datasets.
Discussion
Cystic Fibrosis was first studied as a gastrointestinal disease and was only recognised as a separate disease to coe-
liac disease in 193821. Historically, it was a disease characterized by malabsorption of fats and proteins, resulting 
in steattorhea and pulmonary infection3. Since 2011, the gut microbiota in CF has received renewed attention10–13, 
with studies showing alterations in the CF gut microbiota compared to controls. However, research remains lim-
ited, particularly on what impact such changes have on functionality and to date only one shotgun metagenomic 
study has been completed on the gut microbiota in children with CF, with no adult CF shotgun metagenomic 
study being reported. Our aim was to conduct a proof-of-principle study to investigate if there would be measur-
able changes to the gut microbiota functionality in an adult CF population.
One of the key findings from our pilot study was the enhanced potential for fat metabolism in the CF gut 
microbiota compared to the control group. Pathway and gene family abundances associated with fatty acid bio-
synthesis, fatty acid elongation, and fatty acid metabolism were all significantly increased in the CF gut microbi-
ota compared to the controls. Additionally, the metabolomic results showed higher levels of several fats in the CF 
metabolite profile compared to the controls including octadecanoic acid, hexadecanoic acid and myristic acid. 
It is possible that the enhanced potential of the CF gut microbiota to synthesise and metabolise lipids could con-
tribute to the increased fats seen in the metabolomics data from the CF group. However, it is important to note, 
reduced fat absorption occurs in patients with CF and thus a high fat diet is required to ensure adequate weight 
maintenance. Thus, it is likely that the increased fat metabolites occur as a result of a combination of factors 
including an altered diet, reduced absorption and an altered gut microbiota.
Another finding of our study was the potentially enhanced ability of the CF gut microbiota to metabolise 
xenobiotic compounds compared to the controls. Additionally, pathways and gene families involved in resistance 
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Phylogeny
CF average relative 
abundance





Bifidobacterium 3.20967333 6.81271667 0.05
Bifidobacterium longum 2.12066833 4.23268333 0.046
Bifidobacterium longum_unclassified 2.12066833 4.23268333 0.046
Eggerthella lenta 0.19998833 0.00330333 0.013
Eggerthella lenta|t__GCF_000024265 0.19998833 0.00330333 0.013
Bacteroidetes
Barnesiella 0 1.514735 0.007
Barnesiella intestinihominis 0 1.514735 0.007
Barnesiella_intestinihominis|t__GCF_000296465 0 1.514735 0.007
Alistipes putredinis 0.05026667 4.24946833 0.05
Alistipes putredinis|t__GCF_000154465 0.05026667 4.24946833 0.05
Firmicutes
Bacilli 12.81672 0.78161167 0.016
Lactobacillales 12.456185 0.78161167 0.016
Enterococcaceae 9.54589833 0 0.007
Enterococcus 9.54589833 0 0.007
Enterococcus faecalis 8.832115 0 0.007
Enterococcus faecalis_unclassified 8.832115 0 0.007
Lactobacillaceae 1.59546167 0 0.022
Lactobacillus 0.483995 0 0.022
Streptococcus thermophilus 1.27870833 0.10655 0.049
Streptococcus thermophilus_unclassified 1.27870833 0.10655 0.049
Clostridiaceae 11.9238667 0.50407667 0.004
Clostridium 11.9238667 0.48078667 0.004
Clostridium clostridioforme 6.65942167 0.11350667 0.022
Clostridium clostridioforme_unclassified 6.65942167 0.11350667 0.022
Clostridium hathewayi 0.29948667 0 0.007
Clostridium hathewayi_unclassified 0.29948667 0 0.007
Clostridiales _noname 0.15274667 0.00104167 0.013
Flavonifractor 0.14014 0.00104167 0.05
Flavonifractor plautii 0.14014 0.00104167 0.05
Flavonifractor plautii GCF_000239295 0.14014 0.00104167 0.05
Anaerostipes_unclassified 0.28471833 0 0.007
Blautia 10.2605633 0.89512667 0.016
Blautia producta 0.77242 0 0.022
Blautia producta|t__GCF_000373885 0.77242 0 0.022
Ruminococcus gnavus 8.05991833 0.38045667 0.022
Ruminococcus gnavus_unclassified 8.05991833 0.38045667 0.022
Ruminococcus torques 1.07679 0.054245 0.013
Ruminococcus torques_unclassified 1.07679 0.054245 0.013
Coprococcus 0.17310667 4.51670167 0.033
Coprococcus comes 0.13519667 2.253635 0.021
Coprococcus comes|t__GCF_000155875 0.13519667 2.253635 0.021
Dorea formicigenerans 0.169365 0.73247667 0.049
Dorea formicigenerans_unclassified 0.169365 0.73247667 0.049
Lachnospiraceae bacterium_1_1_57FAA 0.40623667 0 0.007
Lachnospiraceae bacterium_1_1_57FAA|t__GCF_000218445 0.40623667 0 0.007
Lachnospiraceae bacterium_5_1_63FAA 0.01507333 0.414975 0.05
Lachnospiraceae bacterium_5_1_63FAA|t__GCF_000185525 0.01507333 0.414975 0.05
Lachnospiraceae bacterium_8_1_57FAA 0.15276667 0 0.022
Lachnospiraceae bacterium_8_1_57FAA|t__GCF_000185545 0.15276667 0 0.022
Faecalibacterium 0.06931833 3.33589167 0.003
Faecalibacterium prausnitzii 0.06931833 3.33589167 0.003
Faecalibacterium prausnitzii_unclassified 0.06931833 3.33589167 0.003
Table 1. Relative abundances of bacteria found at significantly different levels in the CF and control groups.
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to antibiotics were found in higher abundances in the CF group compared to the controls. These include porin 
activity, penicillin binding, and response to antibiotic changes. Given the high exposure of CF patients to anti-
biotics throughout their lifespan, there is continuous opportunity for the gut microbiota to acquire and develop 
resistance genes and pathways. The CF cohort in this study were exposed to oral, IV, inhaled and long term 
maintenance antibiotics in the 12 months prior to sample collection. This cohort is highly reflective of adult CF 
patients and their typical antibiotic exposure over a 12 month period. Thus they have extensive and prolonged 
exposure to different antibiotics, the majority of which are broad spectrum. By comparing the results from the 
CF group to those from the non-CF control (who had no antibiotic exposure for at least 28 days prior to sam-
pling), we could investigate the impact of a lifetime of antibiotic exposure on gut microbiota composition and 
functionality. Several studies have demonstrated that the human gut microbiota acts as a reservoir of resistance 
and it is most probable that the greater the exposure to antibiotics, the greater the pressure to select for resistant 
microorganisms22–24. This was also highlighted in a recent study that demonstrated higher amoxicillin-clavulanic 
acid resistant Enterobacteriaceae in the faeces of individuals with CF compared to their non-CF siblings25. They 
also suggested that more frequent exposure to this antibiotic in those with CF leads to the development of resist-
ant bacteria in the gut microbiota. The higher abundances of these xenobiotic metabolism and antibiotic resistant 
genes were found in a limited number of microorganisms, which caused the differences between the two groups. 
These included Lachnospiracheae, E. faecalis, Clostridium and Bacteroides. It is interesting to note that E. faecalis 
and C. hathewayi were only identified in the CF gut microbiota and not in the controls. Enrichment of E. faecalis 
levels in CF children has previously been shown18. The antibiotic resistance of E. faecalis is widely recognised 
and has received considerable attention as one of the major threats to human health as a consequence26–28, while 
C. hatewayi has also been linked to human bacteremia and infections29, 30. Detecting increased abundances of 
resistance pathways/genes in these bacteria in the CF gut is unsurprising, but of concern, and likely reflects the 
chronic exposure to antibiotics and their effects on gut microbiota. These results highlight the need for further 
studies ideally investigating such changes in functionality across periods of pulmonary stability, exacerbation and 
post-exacerbation. We hope to conduct such studies, powered based on our current data.
The results also showed significant changes in pathways and gene abundances involved in amino acid metab-
olism between the groups. These included increased arginine and tryptophan metabolic pathways. This suggests 
an enhanced ability of the gut microbiota of individuals with CF to metabolise proteins. It has been well docu-
mented that there is increased catabolism of proteins in CF individuals, leading to excessive energy losses31. These 
results suggest that the altered gut microbiota could potentially add to increased protein catabolism, though 
proof of this is required with transcriptomic and proteomic data. However, our findings are consistent with those 
of a recent study that used faecal proteomics to investigate alterations in gut microbiota and inflammation in 
the CF gut32. The study of 15 children with CF and their unaffected siblings found significant changes in faecal 
proteins in the CF cohort, with a dominance of proteins involved in inflammation and mucus formation in the 
CF group. These changes were associated with changes in faecal microbiota, with increased Enterobacteriaceae 
and Clostridium species and a reduction in F. prausnitzii occurring in the CF group. As was seen in our study, 
increased Clostridium clostridioforme and Ruminococcus gnavus was found in the CF faecal samples. Significant 
reductions of F. prausnitzii observed in that study and ours are consistent with previous findings33. Similarities 
between our adult findings and those of previous studies on CF children18, suggest that the altered gut microbiota 
composition and functionality that occurs in children with CF is maintained through to adulthood in CF patients. 
This demonstrates the need for further investigations in larger adult CF studies going forward.
Figure 5. Score plot from PCA model calculated on the relative concentrations of the variables in the reduced 
dataset. Green: control samples. Red: CF samples. The blue samples in the centre are the QC samples. Data has 
been auto scaled.
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Significant differences also occurred in the metabolite profiles between the 2 groups and we were able to 
accurately predict if a sample was from the CF or control group, based on the metabolite profile alone. However, 
it was not possible in this pilot study to determine which particular metabolites act as a marker of CF, rather a 
combination of metabolites appear to occur as a CF signature. There would be merit in further studying this with 
a larger cohort, having established here that different metabolite profiles occur between CF and control cohorts. 
Additionally, it would be interesting to study how the metabolite profile shifts from stability through exacerbation 
and into the post-exacerbation period. This could help identify if changes in the gut microbiota and faecal metab-
olites could predict exacerbation onset or determine the effects of exacerbation and its treatment on metabolite 
profile.
Ours is the first study to investigate the impact of changes in gut microbiota on functionality in adult CF 
patients using shotgun metagenomics and metabolomics. Previous studies on sputum showed significant var-
iability in the lung microbiota between patients with CF, though the overall functionality remained similar17. 
Additionally, previous studies have shown the human gut microbiota to have considerable redundancy, thus func-
tionality remains similar despite large inter-individual variations in microbiota34, 35. However, our CF gut micro-
biota study showed that both the microbiota composition and functionality was significantly different between 
the CF and control groups. Manor et al. previously demonstrated that the gastrointestinal microbiome of young 
children with CF has an altered functional capacity compared to non CF children, but suggested that this was 
diminished with age18. However, our results demonstrate that there are still measurable changes in gut microbiota 
functionality in an adult CF cohort compared to non-CF controls. Due to the multiple factors that can alter gut 
microbiota in individuals with CF (diet, genetics, antibiotic exposure, pancreatic enzyme use, hospitalization), it 
is not surprising that functionality is also impacted upon, as demonstrated in this study.
Despite the relatively limited sample size in this study, this study demonstrates using in-depth shotgun 
sequencing and metabolomics data, that clear changes occur at both phylogenetic and functional levels between 
the gut microbiota within the two groups. Our study was only conducted on stable CF patients. However, studies 
conducted on stable and exacerbating CF patients would enhance our understanding of the complexities of diet, 
therapeutics and hospitalisation on gut microbiota. Additionally, while our study has shown that the gut microbi-
ota in CF have increased abundances of pathways and genes, meta-transcriptomics and meta-proteomics would 
be required to confirm that these genes are more highly expressed in the CF groups compared to non-CF controls.
To conclude, this is the first study to investigate the gut microbiota of adults with CF using shotgun metagen-
omic sequencing and metabolomics. The results found measurable changes to the gut microbiota phylogeny and 
functionality in the adult CF samples tested. The results are important and provide insights that can shape larger 
future studies so that we can continue to appreciate the role of, and the changes to, the gut microbiota in CF.
Methods
Participants. Fresh faecal samples were collected from 12 individuals (six patients with CF, collected during 
pulmonary stability (aged 23–71) and six healthy controls (aged 20–65 years)). See Supplementary Table S1 and S2 
for clinical characteristics of the CF group. Controls were healthy adults free from gastrointestinal conditions, 
with no antibiotic exposure in the 28 days prior to sample collection. Participants provided written informed 
consent. Four of the six CF patients were pancreatic insufficient. Half of the CF patients were homozygous dF508 
and half were heterozygous dF508. Five of the six patients with CF had oral antibiotics in the previous 12 months 
prior to sample collection (Supplementary Table S2), with the most recent being two weeks prior to sample collec-
tion (CF6). All six individuals with CF had IVs in the previous 12 months, ranging from one-five courses of 14 day 
duration. Five of the six individuals with CF were on long-term oral Azithromycin and all 6 were on nebulized 
antibiotics (Supplementary Table S2). Ethical approval was received from the Clinical Research Ethics Committee 
of the Cork Teaching Hospitals, Cork, Ireland and all experiments were performed in accordance with relevant 
guidelines and regulations. Fresh faecal samples were collected and were immediately frozen at −80 °C between 
collection and DNA extraction, in line with best practice (as previously determined)36 to minimise changes to 
the microbiota.
Metagenomic DNA extraction and Nextera XT preparation. Total metagenomic DNA was extracted 
from the 12 faecal samples as previously described23, 37. DNA was quantified using the Qubit in combination with 
the Invitrogen High Sensitivity DNA assay (BioSciences, Dublin, Ireland). DNA was diluted to 0.2 ng/µl for use 
as input DNA for Nextera XT based preparation for shotgun metagenomic sequencing on the Illumina MiSeq 
platform. Briefly, the DNA was firstly tagmented, whereby the DNA was sheared to ~400–600 bp fragments and 
tagged with Illumina adaptor sequences. An indexing PCR was then completed to individually index each sam-
ple to enable pooling of samples on one flow cell and subsequent bioinformatic demultiplexing. PCR amplicons 
were cleaned and normalised, as per Illumina Nextera XT protocols. To verify the even distribution of samples 
for pooling, qPCR was performed using the Kapa BioSciences MiSeq qPCR quantification kit (KapaBioSciences, 
London, UK).
Illumina MiSeq shotgun sequencing. All metagenomic samples were prepared for sequencing on the 
Illumina MiSeq platform in the Teagasc sequencing facility. Samples were pooled at a concentration of 4pM and 
loaded onto the flowcell and sequenced using a 2 × 300 bp V2 Illumina MiSeq sequencing kit. Four samples were 
sequenced per run, to maximise sequencing depth and coverage.
Quantitative PCR (qPCR) to quantify total bacteria counts in faecal samples. Total bacterial 
counts in the faecal samples were determined using qPCR on the Roche Lightcycler 480 (Roche Diagnostics, 
West Sussex, United Kingdom) as previously described9. A standard curve was established using copy numbers 
of 16S rRNA/μl from 109–102 copies 16S rRNA/μl. The following primers were used: forward primer ACT CCT 
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ACG GGA GGC AGC AG and reverse primer ATT ACC GCG GCT GCT GG. The reaction contained 1 µl DNA, 
5 µl Kapa Mastermix (KK4611), 0.2 µl forward primer (10 nM), 0.2 µl reverse primer (10 nM) and 3.6 µl PCR 
grade water. The following programme was used to quantify total bacterial numbers: denaturation 95 °C × 3 mins 
followed by amplification of 95 °C × 10S, 60 °C × 20S and 72 °C × 1S for 45 cycles, a melting curve: 95 °C × 5S, 
65 °C × 1 min and 97 °C continuous, followed by cooling at 40 °C × 10S.
Faecal water preparation for GC-MS analysis. Faecal water was prepared from each sample for analysis 
by GC-MS. Four hundred milligrams of each frozen faecal sample was used. Twice the volume of PBS was added 
to each faecal aliquot and the sample was homogenized by vortexing. Once completely homogenized, the sample 
was centrifuged at 16,000 g for 30 mins. The supernatant was removed and centrifuged at 16,000 g × 30 mins to 
remove faecal solids. This was repeated twice. The supernatant was then filtered through VectaSpin Micro cen-
trifuge filters (0.2 µm) at 10,000 g for 4–6 mins until all the faecal water had passed through the filter. The faecal 
water was stored at −20 °C until analysis by GC-MS.
GC-MS analysis. All 12 samples were analysed in triplicate. Prior to analysis, all 36 samples were derivat-
ized with methyl chloroformate and subsequently analysed by GC-MS (MS-omics, Fredericksberg, Denmark). 
Samples were analysed in a randomised sequence. From each sample, a small aliquot was pooled to a quality con-
trol (QC) sample and the QC samples were analysed equally spread throughout the sequence. Relative concen-
trations of known and unknown compounds were identified using PARAFAC2. Due to the derivatization, some 
compounds result in more than one peak and the numbers of compounds were therefore lower than the number 
of resolved peaks. In addition, some peaks originate from impurities in solvents. These peaks were removed from 
the data resulting in 99 compounds. Compounds included in the standards were quantified. Testing of matrix 
effects was performed by spiking and dilution of QC samples. It is assumed that the individual sample does not 
have matrix effects not found in the QC samples.
Bioinformatic and statistical analysis. HUMAnN2 analysis of shotgun data. Raw reads were filtered 
based on quality, quantity and length of reads with a combination of Picardtools (http://broadinstitute.github.
io/picard/) and SAMtools38 and human contamination removed with bmtagger (ftp://ftp.ncbi.nlm.nih.gov/pub/
agarwala/bmtagger/). Subsequently function was assigned to reads using the HUMAnN2 suite of tools39; which 
assigned function based on the chocophlan databases and genes based on UniRef40. The HUMAnN2 gene abun-
dance table was regrouped using a mapping of GO terms that descend from |BP|03|cellular amino acid metabolic 
process, |BP|03|carbohydrate metabolic processes, |BP|03|lipid metabolic processes and |BP|03|xenobiotics met-
abolic processes to UniRef families. This was done separately for each of these metabolic processes. MetaPhlAn2 
was used to extract taxonomical profiles from the shotgun sequencing results. Graphical representation of the 
MetaPhlAn2 results were generated using the GraPhlAn software19, 20, 41.
Statistical analysis. Statistical analysis was conducted using the R statistical software package (3.2.2). 
Non-parametric Kruskall Wallis tests were conducted on the GC-MS metabolite data, pathway abundances and 
gene family abundances, with p < 0.05 accepted as a significant result (all values have been corrected for multiple 
testing with the benjamini-hochberg method). Principle coordinate analysis (PCA) and heat maps were generated 
using the ggplots2, gplots, Rtools, devtools and cluster packages in R. The 3D scatter plots were generated with the 
following axes: on the x-axis carbohydrate metabolic process = GO:0005975|BP|03|, lipid metabolic process on 
the y-axis = GO:0006629|BP|03| and as the z-axis xenobiotic metabolic process = GO:0006805|BP|03| or cellular 
amino acid metabolic process GO:0006520|BP|03|. These were generated using the R statistical packages car and 
rgl. Procrustes and co-inertia analysis were used to compare metabolomic and metagenomic datasets also in R.
Data Availability. Data is available through http://www.ebi.ac.uk/ena/data/view/PRJEB21353 with project 
accession # PRJEB21353.
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